in

How to tackle vaccine innovation for infectious diseases

Only McKinsey Perspectives

DELIVERING ACTIONABLE INSIGHTS ON THE DAY’S NEWS

Brought to you by Alex Panas, global leader of industries, & Axel Karlsson, global leader of functional practices and growth platforms

Welcome to the latest edition of Only McKinsey Perspectives. We hope you find our insights useful. Let us know what you think at Alex_Panas@McKinsey.com and Axel_Karlsson@McKinsey.com.

—Alex and Axel

Vaccine innovation at a crossroads

In the news

•

Antiparasitic-vaccine challenges. Parasites cause numerous diseases around the world. Among the most neglected tropical diseases, notes WHO, are parasitic illnesses. Yet parasites are not sufficiently researched, and funding for solutions, including vaccines, is lacking, reports the BBC. The recently rolled-out antimalarial vaccine is the world’s only parasitic vaccine. Traditional vaccine developers typically haven’t prioritized parasitic diseases, because they are tough to study, are often not fatal, and are most prevalent in low- and middle-income countries, among other reasons. [BBC]

•

Pandemic treaty pushed back. After hoping for a June agreement on a treaty for how to better fight future pandemics, more than 190 countries are now expected to conclude their talks by 2025, according to Reuters. The countries have been in negotiations for two years to develop an agreement that would help ensure that mistakes made during the COVID-19 pandemic are not repeated. However, wealthy countries and those that are less well off have struggled to agree on topics such as sharing vaccines. [Reuters]

Addressing disparities and accelerating vaccine development for unmet needs remain crucial in the ongoing fight against infectious diseases.

On McKinsey.com

•

Postpandemic vaccine landscape. The COVID-19 pandemic highlighted the critical role that vaccines play in public health. During the pandemic, several factors combined to spur rapid vaccine development: increased funding, operational efficiencies, technological progress, and regulatory adaptability. Yet success for other vaccine archetypes has been uneven, say McKinsey senior partner Adam Sabow and coauthors. Apart from COVID-19, the number of vaccine programs for infectious diseases remains mostly static.

•

Harnessing pandemic lessons. The pandemic did, however, lead to a 30% overall increase in vaccine candidates in the past five years, giving vaccine makers a new model to consider. The vaccine ecosystem is now at a crossroads: Will it return to being more vulnerable to business challenges, or will it learn from the pandemic and maintain or even boost vaccine innovation? Learn about five actions stakeholders can take to overcome investment barriers, regulatory challenges, and market uncertainties in the ongoing effort to accelerate vaccine innovation and tackle global health.

Accelerate vaccine development

—Edited by Querida Anderson, senior editor, New York

Was this forwarded to you? Sign up here.

Or send us feedback—we’d love to hear from you.

Follow our thinking

McKinsey Insights - Get our latest thinking on your iPhone, iPad, or Android.

This email contains information about McKinsey's research, insights, services, or events. By opening our emails or clicking on links, you agree to our use of cookies and web tracking technology. For more information on how we use and protect your information, please review our privacy policy.

You received this email because you subscribed to the Only McKinsey Perspectives newsletter, formerly known as Only McKinsey.

Manage subscriptions | Unsubscribe

by "Only McKinsey Perspectives" <publishing@email.mckinsey.com> - 01:12 - 9 Sep 2024

Archives

in

info@learn.odoo.com

Unpacking the Sales Cloud Keynote: Driving Growth with AI

Look inward to move forward: A leadership journey

How to tackle vaccine innovation for infectious diseases

Vaccine innovation at a crossroads

In the news

Addressing disparities and accelerating vaccine development for unmet needs remain crucial in the ongoing fight against infectious diseases.

On McKinsey.com

Archives

in

info@learn.odoo.com

Unpacking the Sales Cloud Keynote: Driving Growth with AI

Look inward to move forward: A leadership journey

How to tackle vaccine innovation for infectious diseases

Vaccine innovation at a crossroads﻿

In the news

Addressing disparities and accelerating vaccine development for unmet needs remain crucial in the ongoing fight against infectious diseases.﻿

On McKinsey.com

Vaccine innovation at a crossroads

Addressing disparities and accelerating vaccine development for unmet needs remain crucial in the ongoing fight against infectious diseases.